Journal
VIRCHOWS ARCHIV
Volume 461, Issue 3, Pages 245-257Publisher
SPRINGER
DOI: 10.1007/s00428-012-1281-4
Keywords
Anaplastic lymphoma kinase; Rearrangement; Crizotinib; Algorithm; Guidelines; Non-small cell lung cancer
Categories
Funding
- Pfizer
Ask authors/readers for more resources
In non-small cell lung cancer, epidermal growth factor receptor gene mutations and anaplastic lymphoma kinase (ALK) gene rearrangements have a major impact upon the level of response to treatment with specific tyrosine kinase inhibitors. This review describes the molecular basis of ALK inhibition, summarizes current data on the effectiveness and safety of ALK inhibition therapy, describes the different testing methodologies with their advantages and disadvantages, provides a suggested testing algorithm and puts forward a proposal for an external quality assessment program in ALK testing.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available